Citigroup maintains Regeneron Pharmaceuticals at Neutral, raises price target to $825 from $740

What happened

Citigroup kept its Neutral rating on Regeneron Pharmaceuticals and raised its price target to $825 from $740, an 11.5% increase. The new target implies an 11.1% downside from the October close of $927.89 per share.

Confirmed

Global impact / market context

A Neutral rating means Citigroup sees limited upside, and its $825 target sits below the $927.89 close. That gap suggests the broker views the stock as fairly valued after its run, so this note gives investors no strong buy signal.

Analyst inference

Recent analyst targets on Regeneron range from $810 to $980, so Citigroup's $825 sits near the low end. The mix of Buy, Overweight, and Sector Perform ratings shows divided views, with some firms expecting far more upside than Citigroup does.

Analyst inference

What to watch

1. Citigroup's $825 target implies an 11.1% downside from the October close of $927.89, so watch whether the share price moves toward or away from that level. Confirmed
2. Watch for further analyst notes, since the five most recent targets span $810 to $980, which suggests firms may keep adjusting their views on Regeneron. Proposed
3. Watch Regeneron's upcoming results and drug updates, because rating and target changes likely follow shifts in expected revenue and profit per sale. Analyst inference

Evidence

• Original source link unavailable